Orexigen's Mysimba™ Approved in Europe for the Treatment of Obesity
March 26, 2015The European Commission has granted marketing authorization for Orexigen's Mysimba™ for the management of weight in adult patients to supplement a reduced-calorie diet and increased physical activity.
More »
MARINUS PHARMACEUTICALS’ GANAXOLONE RECEIVES FDA ORPHAN DRUG DESIGNATION IN PCDH19 FEMALE EPILEPSY
March 25, 2015The FDA grants Orphan Drug Designation for Marinus Pharmaceuticals' ganaxolone for the treatment of protocadherin 19 gene (PCDH19) female epilepsy, which is currently in Phase 2 clinical trials.
More »
Aldeyra Therapeutics Announces First Patient Enrolled in Sjogren-Larsson Syndrome Phase II Clinical Trial
March 24, 2015Aldeyra Therapeutics enrolls the first patient in its Phase II clinical trial of NS2 for the treatment of Sjögren-Larsson Syndrome at the University of Nebraska University Medical Center, the leading treatment center in the country for SLS.
More »